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Summary
Good’s syndrome (thymoma and hypogammaglobulinaemia) is a rare sec-
ondary immunodeficiency disease, previously reported in the published 
literature as mainly individual cases or small case series. We use the na-
tional UK-Primary Immune Deficiency (UKPID) registry to identify a 
large cohort of patients in the UK with this PID to review its clinical 
course, natural history and prognosis. Clinical information, laboratory 
data, treatment and outcome were collated and analysed.  Seventy-eight 
patients with a median age of 64  years, 59% of whom were female, were 
reviewed. Median age of presentation was 54  years. Absolute B cell num-
bers and serum immunoglobulins were very low in all patients and all 
received immunoglobulin replacement therapy. All patients had undergone 
thymectomy and nine (12%) had thymic carcinoma (four locally invasive 
and five had disseminated disease) requiring adjuvant radiotherapy and/
or chemotherapy. CD4 T cells were significantly lower in these patients 
with malignant thymoma. Seventy-four (95%) presented with infections, 
35 (45%) had bronchiectasis, seven (9%) chronic sinusitis, but only eight 
(10%) had serious invasive fungal or viral infections. Patients with AB-
type thymomas were more likely to have bronchiectasis. Twenty (26%) 
suffered from autoimmune diseases (pure red cell aplasia, hypothyroidism, 
arthritis, myasthenia gravis, systemic lupus erythematosus, Sjögren’s syn-
drome). There was no association between thymoma type and autoim-
munity. Seven (9%) patients had died. Good’s syndrome is associated with 
significant morbidity relating to infectious and autoimmune complications. 
Prospective studies are required to understand why some patients with 
thymoma develop persistent hypogammaglobulinaemia.
Keywords: agammaglobulinaemia, autoimmunity, bronchiectasis, Good’s 
syndrome, thymoma
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Introduction
Thymomas are rare tumours of thymic epithelium, origi-
nally derived from the endodermal lining of the third 
pharyngeal pouch. They have recently been linked to 
mutations in the thymoma-specific transcription factor 
regulating growth factor signalling GTF2I and, to a lesser 
extent, HRAS, NRAS and TP53 [1,2]. Thymomas typically 
present in adults aged 40–60 years, with only a few cases 
described in children [3]. Approximately half the tumours 
are encapsulated, and only 10% relapse after surgery [4].
Thymomas commonly trigger paraneoplastic autoim-
mune complications affecting the nervous system and bone 
marrow precursors [4,5]. Disorders of the nervous system 
are secondary to autoantibodies disrupting neural trans-
mission, e.g. anti-acetylcholine receptor antibodies in 
myasthenia gravis (occurring in 17–40% of patients with 
thymoma); anti-glutamic acid decarboxylase (GAD65) and 
anti-glycine receptor antibodies in Stiff-person syndrome; 
anti-Kv1 Voltage-Gated K+ Channels (VGKC) or anti-
Contactin-associated protein-like 2  (Caspr2) antibodies 
in acquired neuromyotonia and autoimmune encephalitis; 
and anti-P/Q-type Voltage-Gated Calcium Channels 
(VGCC) antibodies in Lambert–Eaton syndrome and auto-
immune encephalitis [6]. The most common disorders 
affecting bone marrow precursors are pure red cell aplasia 
(PRCA) and ‘pure B cell aplasia’ (Good’s syndrome: thy-
moma and hypogammaglobulinaemia) (3–4% of patients). 
A few patients have also been described with agranulo-
cytosis, myelodysplasia or paroxysmal nocturnal haemo-
globinuria [7‒9]. The pathogenesis of these complications 
is thought to involve either the production of autoanti-
bodies, e.g. anti-erythropoetin antibodies in PRCA, or 
destruction of bone marrow precursors by CD8 T lym-
phocytes in PRCA and Good’s syndrome [10‒14].
Since the original description by Dr Robert Good 
more than 60 years ago, most publications of Good’s 
syndrome are single case reports or small case series, 
the previous largest being a systematic review of 
47 Chinese patients [15], and a compilation of 152 cases 
from cases published prior to 2010 [10]. The aim of 
our survey was to review the clinical and laboratory 
features of patients with Good’s syndrome identified 
through the UK-PIN immunodeficiency registry and 
investigate what factors may be associated with specific 
complications and outcome.
Methods
Patient definition and identification
Patients with thymoma were identified from 14  clinical 
immunology referral centres across the United Kingdom 
contributing patients to the national UK-Primary Immune 
Deficiency (UKPID) registry. All had associated hypogam-
maglobulinaemia consistent with a diagnosis of Good’s 
syndrome. This registry was established in 2009 and 
recruited patients prospectively after obtaining written 
consent. Permission from principal investigators of each 
centre is required before their data can be accessed and 
studied and those centres with registered cases of Good’s 
syndrome were approached. All responded and consented 
to take part in the study. The registry currently contains 
4758 patients with primary immunodeficiency diseases, 
78 (1.6%) of whom are classified as having thymoma and 
hypogammaglobulinaemia.  As patients were added to 
the UKPID registry prospectively as part of regular patient 
care, mortality data are limited to those dying during the 
last 9  years.
The study had multi-centre ethical approval (04/
MRE07/68). After requesting permission from Centre 
Principle Investigators, data were collated into a single 
spss database (IBM SPSS Statistics 22.0) for analysis. 
Clinical information included demographics, past medical 
history of acute or recurrent respiratory tract infections 
and non-infectious complications. UKPID registry entries 
are updated on an annual basis to ensure that subsequent 
morbidity and mortality, as well as latest laboratory param-
eters, are recorded. For the purposes of this survey, registry 
entries were rechecked with source data by M.Z., P.D.A. 
and centre investigators and where possible missing data 
points were filled. Clinical complications for which data 
were available included respiratory tract infections (RTI), 
myasthenia gravis, pure red cell aplasia and hypogam-
maglobulinaemia. Therapies, including surgery, radio-
therapy and chemotherapy for the thymoma, and 
immunoglobulin replacement therapy for the antibody 
deficiency were also recorded.
Laboratory investigations
Laboratory data included routine haematology [haemo-
globin, white blood count (WBC), absolute neutrophil 
and lymphocyte counts, and platelets] and immunology 
[lymphocyte subsets: absolute CD3, CD4, CD8, CD19, 
CD56 and serum immunoglobulin (Ig) concentrations] 
recorded at diagnosis and on immunoglobulin replace-
ment therapy. Lymphocyte subsets were assessed using 
standard immunofluorescent staining and flow cytometry 
was performed in accredited regional clinical immunology 
laboratories. Proliferative T cell responses were not 
requested. Serum immunoglobulin concentrations were 
measured by nephelometry. Vaccine responses were not 
requested on the majority of patients, as serum immu-
noglobulin concentrations were so low. Thymomas were 
classified histologically according to the World Health 
Organization (WHO) classification of tumours of the 
thymus [16].
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Statistical analysis
Analysis was conducted using the IBM spss Statistics ver-
sion 22.0 program. Continuous variables are quoted as 
medians and interquartile ranges. Statistical differences 
between groups were determined by χ2, Kruskal–Wallis 
and Mann–Whitney U-tests. Spearman’s rho test was used 
to assess the correlation between continuous variables. 
Differences were considered statistically significant with 
a P-value <  0·05 unless otherwise stated.
Results
Demographics of the cohort
Data were collected from 78  patients with thymoma and 
hypogammaglobulinaemia (Good’s syndrome) with a 
median age at evaluation of 64  years (range  =  24–90). 
There were 32  males (41%) and 46  females (59%), with 
no reported familial cases. Seventy-six (97%) patients were 
white European. Fifty-five (71%) were from England, 14 
(18%) from Scotland, five (6%) from Northern Ireland 
and four (5%) from Wales.
Clinical features (Table 1)
The median age at which symptoms appeared was 54 
(interquartile range = 48–60) years. Median age of diagnosis 
of hypogammaglobulinaemia [58 (51–62) years] and thy-
moma [58 (51–62) years] were the same and a median of 
4 years later. In 58 (74%) patients, the diagnosis of hypogam-
maglobulinaemia and thymoma were concurrent. In nine 
(12%) patients, the diagnosis of hypogammaglobulinaemia 
was 1–8 years prior to finding the thymoma and in 11 
(14%) patients hypogammaglobulinaemia was diagnosed 
1–6 years after finding the thymoma. In 74 (94%) patients 
the initial symptoms were recurrent sinopulmonary infec-
tions, with 35 (45%) having radiological evidence of bron-
chiectasis. Seven patients (9%) had chronic sinusitis. Three 
patients suffered from candidiasis, three from retinal cyto-
megalovirus (CMV) and toxoplasmosis, one from persistent 
warts and one died of progressive multi-focal encepha-
lopathy. Only two patients had problems with diarrhoea, 
one of whom was diagnosed with ulcerative colitis.
Autoimmunity was documented in 20  patients (26%), 
with pure red cell aplasia in eight (10%), hypothyroidism 
in six (8%), inflammatory arthritis in four (5%), myasthenia 
Fig. 1. Age of diagnosis (years) in relation to whether or not the patients had (a) bronchiectasis or (b) autoimmune disease. Blue line = no disease; 
green line = disease.
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gravis in three (4%), systemic lupus erythematosus (SLE) 
in three (4%) and Sjögren’s syndrome in two (3%). Patients 
with red cell aplasia were not more likely to have myas-
thenia gravis or hypothyroidism. All the patients with 
hypothyroidism were female, while for the other autoim-
mune disorders there was no significant propensity to the 
female gender. The age at diagnosis of the patients with 
bronchiectasis or autoimmunity were not significantly dif-
ferent from patients without these complications (Fig. 1).
Six patients (8%) had additional non-thymic tumours 
(two basal cell carcinoma, one renal cell carcinoma, one 
breast carcinoma, one cervical carcinoma and one lung 
cancer). There was no significant association between 
thymic and extra-thymic cancer. Seven (9%) patients had 
died, two of metastatic thymoma, two of bacterial sepsis, 
one of progressive multi-focal encephalopathy and the 
causes of death in the other two (one of whom was aged 
90  years old) were unclear.
Investigations
Chest computerized tomography (CT) scan was the pre-
ferred diagnostic procedure to identify both the thymoma 
and assess lung disease. Pathology and staging reports 
were available for 46 (59%) of the 78  patients (Table 2), 
as some patients had their surgery performed at a dif-
ferent hospital, and unfortunately pathology results were 
not relayed to the primary physician. Nine patients (12%) 
had evidence of thymic carcinoma, four locally invasive 
and five distally disseminated. Sixteen of 27 (59%) patients 
with stage AB disease had bronchiectasis compared with 
only three of 16 (19%) patients with other thymoma types 
(P  =  0·02). There was no correlation between thymoma 
type and autoimmune complications.
Haematology and immunology results are shown in 
Table 3. Absolute B cell (CD19) numbers were less than 
0·0 × 109/l, and serum immunoglobulin (Ig)M, IgG (prior 
to starting immunoglobulin replacement therapy) and IgA 
were well below the normal reference ranges. Patients 
with malignant thymomas (stage IV, classification C) had 
significantly lower absolute CD3+CD4+ counts compared 
with non-malignant tumours (Table 4, Fig. 2). In fact, 
all patients with stage IV disease had absolute CD4 counts 
<  0·25  ×  109/l compared with only 15% of patients with 
stages I–III. CD4/CD8 ratios did not vary significantly 
between the histological groups (P  =  0·1). Neither stage 
Table 2. Staging and pathology of thymoma
Stage
I Completely encapsulated 32 (66%)
II Invasion through thymic capsule 8 (16%)
III Local invasion into neighbour-
ing organs
4 (8%)
IV Pleural/pericardial dissemina-
tionLymphogenous/
hematogenous spread
5 (10%)
Pathology
A Medullary, spindle cell thymoma 4 (9%)
AB Mixed thymoma 27 (59%)
B1–3 Cortical thymoma (B3: 
well-differentiated thymic 
carcinoma
6 (13%)
C Thymic carcinoma 9 (19%)
Pathology reports were available for 46 of the 78 patients. Based on 
Masaoka[16].
Table 3. Laboratory parameters
Parameter Result Normal range
Haemoglobin (g/l) 133 (125–145) 115–165
WBC (× 109/l) 6·1 (4·3–8·6) 4·0–11· 0
Neutrophils (× 109/l) 3·8 (2·4–6·0) 1·80–7·50
Lymphocytes (× 
109/l)
1·5 (0·9–2·5) 1·00–4·00
Platelets (× 109/l) 250 (177–328) 150–400
CD3 (× 109/l) 1·08 (0·53–2·05) 0·62–2·40
CD4 (× 109/l) 0·53 (0·31–0·70) 0·50–1·50
CD8 (× 109/l) 0·52 (0·20–1·06) 0·19–0·90
CD4/CD8 ratio 0·93 (0·62–1·38) 0·72–2·56
CD19 (× 109/l) 0·00 (0·00–0·00) 0·12–0·64
CD56 (× 109/l) 0·11 (0·00–0·11) 0·02–0·41
IgM (g/l) 0·09 (0·04–0·20) 0·50–2·0
IgG (g/l) 2·92 (1·85–4·10) 6·0–16·0
IgA (g/l) 0·20 (0·09–0·40) 0·8–2·80
Numbers for continuous variables represent medians (interquartile 
ranges). Figures in red indicate that they are lower than the stated nor-
mal range. Immunoglobulin (Ig)G measurements were all before pa-
tients started on immunoglobulin replacement.
Table 1. Demographic and clinical parameters Parameter
Age (years) 64 (58–71)
Gender 46 (59%) female
Ethnicity 76 (97%) white European
Age of onset of symptoms (years) 54 (48–60)
Age at diagnosis of hypogammaglob-
ulinaemia (years)
58 (51–62)
Age of diagnosis of thymoma (years) 58 (51–62)
Clinical features
Bronchiectasis (on chest CT scan) 35 (45%)
Chronic sinusitis 7 (9%)
Autoimmunity 20 (26%)
Red cell aplasia 8 (10%)
Thyroid 6 (8%)
Arthritis 4 (5%)
Myasthenia 3 (4%)
SLE 3 (4%)
Sjögren’s disease 2 (3%)
Died 7 (9%)
Figures represent number (percentage) for discrete variables and me-
dian (interquartile range) for continuous variables. SLE = systemic lu-
pus erythematosus; CT = computerized tomography.
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Table 4. Clinical and laboratory parameters based on World Health Organization (WHO) histological type
Parameter A AB B C P-value
Number 4 27 6 9
Age (years) 62 (62–69) 64 (56–73) 67 (55–78) 59 (54–62) 0·1
Age onset 54 (33–61) 54 (44–60) 60 (52–69) 52 (40–56) 0·1
Females 2 (50%) 20 (74%) 4 (67%) 4 (44%) 0·4
Abs lymphs 2·5 (1·9–3·2) 1·6 (1·1–2·5) 2·3 (1·0–2·6) 0·8 (0·5–0·9) 0·003
Abs CD3 2·8 (2·3–4·1) 1·1 (0·8–2·2) 0·7 (0·4–1·7) 0·7 (0·4–0·9) 0·02
Abs CD4 0·6 (0·3–1·0) 0·6 (0·4–1·0) 0·4 (0·2–) 0·2 (0·1–0·3) 0·02
Abs CD8 1·4 (0·3–3·5) 0·7 (0·2–1·5) 0·2 (0·1–) 0·3 (0·2–0·5) 0·3
Autoimmune 1 (25%) 6 (22%) 1 (17%) 4 (44%) 0·6
Myasthenia 1 (25%) 1 (4%) 0 1 (11%) 0·3
RBC aplasia 3 (9%) 2 (7%) 0 3 (33%) 0·1
Bronchiectasis 1 (25%) 16 (59%) 0 2 (22%) 0·02
Figures for continuous variables represent medians (interquartile ranges). Immunoglobulin (Ig)G measurements were all before patients started on 
immunoglobulin replacement. Statistical differences between groups determined by Kruskal–Wallis U-test for continuous variables or χ2 test for 
discrete variables. Abs = absolute; RBC = red blood cells.
Fig. 2. Association between World Health Organization (WHO) histology type and absolute blood (a) lymphocyte, (b) CD3 count, (c) CD4 count, 
(d) CD8 count, (e) CD4/CD8 ratio. Box plots represent median and interquartile ranges. *P < 0·05 by Kruskal–Wallis and Mann–Whitney U-tests.
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nor absolute T lymphocyte count were significantly associ-
ated with autoimmunity.
Management
All patients had undergone thymectomy and were on 
replacement immunoglobulin replacement therapy, admin-
istered either subcutaneously or intravenously. In addition 
to surgical resection, six patients were treated with radio-
therapy, four with chemotherapy and three with both 
radiotherapy and chemotherapy.
Discussion
We present the largest primary case series of Good’s syn-
drome published to date. A review of 152  collated cases 
published in the literature prior to 2010 [10] is the only 
larger series, collecting previously published cases. The 
age of onset of symptoms of the 78  UK patients ranged 
from 24 to 90  years and there were no children, in keep-
ing with previous studies. Diagnosis of the thymoma and 
hypogammaglobulinaemia was concurrent in three-quarters 
of the patients in this cohort. This might be expected, as 
all the patients were recruited to the UKPID registry by 
clinical immunologists caring for the patients’ hypogam-
maglobulinaemia. Chest symptoms are common in 
hypogammaglobulinaemia and chest radiographs would 
be part of the work-up for these patients, leading to dis-
covery of the mediastinal mass. Patients came from around 
the United Kingdom, with no specific ‘hot-spots’. Most 
patients (94%) presented with infections and nearly half 
(45%) had radiological evidence of bronchiectasis. Although 
there were numerical reductions of T cells in a number 
of patients, infections usually associated with T cell defi-
ciencies were not a prominent feature of this cohort, which 
is at odds with reported smaller studies [17,18]. Three 
patients had candidiasis, but antibiotics may have con-
tributed to this problem. Two had problems with retinal 
CMV and toxoplasmosis and one died of progressive 
multi-focal encephalopathy. Diarrhoea was not a prominent 
problem of this cohort, in contrast to another case series 
where it occurred in 38% [10]. Twenty-three per cent 
had evidence of other autoimmune disorders, the most 
commonly being PRCA (9%), with only 4% having myas-
thenia gravis, the predominant autoimmune disorder 
overall in patients with thymoma. Two patients (3%) had 
a significant neutropaenia with an absolute neutrophil 
counts less than 1·0  ×  109/l. Eleven patients (15%) had 
a low platelet count of between 40 and 130  ×  109/l. These 
findings might suggest that similar immune mechanisms 
underlie disorders of bone marrow precursors.
As with previous studies, the most common histological 
type was AB, with 58% having a moderate infiltrate of 
thymocytes [4,10]. The majority of tumours were benign, 
with only 19% spreading outside the capsule. This cohort 
seemed to have a more benign course than previously 
published series of thymoma patients not selected on the 
basis of hypogammaglobulinaemia, where more than half 
of patients’ tumours were invasive and 28% of patients 
had died [19,20]. In our cohort, only nine patients (11%) 
had thymic carcinoma and seven patients (9%) had died, 
two from their metastatic thymoma and three from infec-
tions. As with our previous study of patients with idi-
opathic hypogammaglobulinaemia, we found an association 
between a malignant phenotype and low T lymphocyte 
numbers, which might suggest a lack of immune surveil-
lance in these patients [21].
A limitation of this study is that histology was only 
available for 46 of the 78  patients, as in a number of 
cases the thymectomy was carried out at a different centre 
and the histological report was not transferred to the 
immunologist looking after the patient.
In contrast to patients with common variable immu-
nodeficiency (CVID), a prominent feature of patients 
with Good’s syndrome is the almost complete absence 
of B cells. Our understanding of the pathogenesis of 
Good’s syndrome is still very much in its infancy. Unlike 
patients with thymomas suffering from myasthenia gravis, 
where a third improve after thymectomy, we observed 
no improvement in the hypogammaglobulinaemia or B 
cell deficiency in our patients with Good’s syndrome 
after thymectomy [22]. Research studies using bone mar-
row immunophenotyping are required to examine the 
stage at which B cell development is being disrupted 
[23]. Prospectively, this could best be performed alongside 
thoracic surgery, reducing the need for additional hospital 
admissions and the discomfort of the procedure. In view 
of previous published findings which show over-expression 
of specific CD8 clones by spectrotyping analysis, CD8 
T cell phenotyping in bone marrow aspirates should also 
be performed to determine to what extent clonal pro-
liferation of cytotoxic T cells was involved in the patho-
genesis [11,12]. Additionally, serum should be investigated 
for evidence of autoimmunity as a cause of immunode-
ficiency. This may manifest, for instance, as anti-cytokine 
antibodies or B cell precursor destruction.
A clearer understanding of the immune mechanisms 
underlying Good’s syndrome may not only suggest more 
focused therapies for this condition, but may also promote 
the development of novel drug targets in patients with 
antibody-mediated autoimmune disorders and patients 
who have become resistant to biologicals because of neu-
tralizing antibodies.
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